Introduction
Data on the burden of a disease have gained wide spread use in evidence based health policy (Murray and Lopez, 1996a) . The World Health Organization (WHO), Harvard University and the World Bank have published several studies with estimates of the global burden of diseases Lopez, 1996b, 1997a-c; Mathers et al., 2002) . Those studies generally show, as is seen in Table 1 , that mental illness in Europe is the disease group with the highest share of disability-adjusted life-years (DALYs). It accounts for about one quarter of all DALYs lost (Kaplan and Laing, 2004) .
A number of disorders of the brain are not visible in the summary tables, because WHO lists them elsewhere (e.g. stroke under cardiovascular diseases, traumatic brain injury under trauma). However, in a separate study, based on WHO data, brain disorders were estimated to represent 35% of the total burden of all diseases in Europe (Olesen and Leonardi, 2003) . Hence, this already suggests that the cost of brain disorders in Europe is very high.
Whilst burden of disease data are interesting and relevant, they do not tell us anything about the cost of different diseases and where those costs occur. Such information is needed in order to compare how health care resources are used in relation to the overall cost of illness and burden of disease. Cost of illness studies are thus complementary to burden of disease studies, and they are indispensable for policy makers.
The primary objective of this project is to provide the best possible estimate of the burden of brain disorders in Europe, based on the available literature and data. The secondary objective is to identify shortcomings in the presently available health economic and epidemiologic data base on brain disorders in Europe and to suggest future research. Furthermore, the project aims at stimulating the collaboration between health economists and epidemiologists in the research field of brain disorders in Europe in order to ensure improvements in future research.
Europe is in this study defined as the EU 25 countries plus Iceland, Norway and Switzerland (see Fig. 1 ). Some countries in Eastern Europe have been excluded from this study, due to resource limitations and the fact that relevant data are missing.
Materials and methods
The study is based on epidemiologic and economic data for 12 defined disorders of the brain. We have decided to use the term disorders instead of diseases, which for some mental disorders 1 is not universally accepted. However, when it is relevant in the text, we may interchangeably use the term disease or illness. The 12 disorders were included in the study as they represent the most prevalent and expensive disorders of the brain. However, the inclusion and grouping of diseases is not self evident and may be expanded or changed in future studies, based on the experience in this study. There may be good reasons to include additional diseases, or to group them in a different way. The latter is particularly relevant for the mental disorders, where the grouping of disorders is less homogeneous than for the neurological disorders. Some groups of disorders of the brain are not included in our study due to heterogeneity or lack of data: eating disorders, somatoform disorders, neuromuscular disorders and developmental disorders.
Data were mainly collected from the literature. The following sections describe the data used in the study, as well as the methodology to estimate the total cost of a specific brain disorder in a specific country based on available data. A model was developed for imputation of costs for combinations of disorders and countries where data did not exist, based on the data available in other countries.
Economic data
The economic data on brain disorders in Europe were based on extensive reviews of available evidence in the literature. The reviews were conducted by health economists. Studies with at least an abstract in English were identified using essentially Medline and HEED (Health Economic Evaluations Database). All abstracts were screened and studies selected if they: 1 contained full or partial cost of illness information; 2 concerned any European country; 3 were not based on a clinical trial; 4 and were not limited to a specific treatment or a short treatment episode. Economic evaluations were only included if they contained basic cost of illness information with standard care and if no other information for the country was available. Analyses using data from cost of illness studies published separately or publications relating to already published basic data were excluded, as were review studies, commentaries, and pure quality of life studies. Studies providing utility measures for defined types of patients were included to allow estimation of intangible costs. For brain disorders where little evidence was found in Medline or HEED, literature searches were also employed in other European sources such as: governmental bodies, patient organizations and research institutes. However, limitations in our literature search should be noted, as no evidence was reviewed in local languages, e.g. studies conducted in Central and Eastern European countries. Moreover, the omission of economic evolutions may have constrained the amount of evidence obtained. For a more detailed description of the methodology and results from the reviews, see previous publications by disease area (AndlinSobocki, 2004; Berg, 2004a,b; Ekman, 2004a,b; Ekman and Forsgren, 2004; Jo¨nsson, 2004; Kobelt, 2004; Lindgren, 2004; Lothgren, 2004a-c) 2 . Cost data were presented in terms of average cost per patient, and stratified by age, gender and disease severity where the published evidence allowed it. The inclusion of resource use components varied between the different brain disorders according to availability of data (see Table 2 ).
For most mental disorders, resource use outside the health care sector is not available but it is expected to be high. The existence of data indicated in Table 2 , does not mean that it was complete, or present for many countries. But there was enough data for use in the model estimating total cost. For a more detailed description of the economic input data for the present study see the section Part II. Epidemiologic and economic evidence in specific brain disorders in Europe. 
National statistics
National and international statistics were collected from international data sources for the model. Population statistics and national welfare statistics (e.g. gross domestic product, healthcare expenditure) were retrieved from the Eurostat database 2004 (Eurostat, 2004a) and OECD Health database 2004 (OECD, 2003 . Cost data were inflated to year 2004 with the consumer price index (Eurostat, 2004b; Bureau of Labour Statistics, 2005) , and converted to Euros (€), adjusted with purchasing power parity (European Central Bank, 2004; Eurostat, 2004c) . Indexes were calculated based on national welfare statistics and price level indexes retrieved from the Eurostat database 2004 (European Central Bank, 2004 Eurostat, 2004c) . In Table 3 the most relevant national statistics used in the study are presented.
Epidemiology data
The epidemiology data used in this study are based on a systematic review of published epidemiology data in Europe (Wittchen and Jacobi, 2005) . The extensive reviews were based on published evidence. The main source used for the reviews were electronic databases (MedLine and Web of Science) complemented with national registries and the Internet. Twelve international groups of epidemiologists worked on the project, each group with expertise in the epidemiology of one of the brain disorders covered by the project (see Acknowledgements for names and affiliations). All reviews resulted in articles which were published early 2005 (Berr et al., 2005; Campenhausen et al., 2005; Fehm et al., 2005; Forsgren et al., 2005; Goodwin et al., 2005; Lieb et al., 2005; Paykel et al., 2005; Pini et al., 2005; Pugliatti et al., 2005; Ro¨ssler et al., 2005; Rehm et al., 2005a,b; Servadei et al., 2005; Stovner et al., 2005; Truelsen et al., 2005; Westphal et al., 2005; Wittchen and Jacobi, 2005) 3 . The multinational experts included in the data collection ensured the review of all possible data including local sources as well as grey literature. Twelve months prevalence data were collected in all areas of brain disorders by country. Moreover, data were stratified on age, gender and disease severity where published evidence allowed it. In countries where no epidemiology data were available in the literature, the review group of epidemiology experts in each disease area made best estimates for the specific country or extrapolated from available data. Where multiple studies were available for one country, the most representative data were used. For a more detailed description of the epidemiologic input data used in the present study see the section Part II. Epidemiologic and economic evidence in specific brain disorders in Europe.
Cost-of-illness methodology
The basic principle in costing is that resources should be valued according to their Ôopportunity costÕ (i.e. the cost in terms of opportunities lost). This means that the best alternative use for the resources should be decided and the cost then considered in relationship to that. As it is not possible to observe this opportunity cost directly, we are in practice limited to the observation of Ôaccounting costsÕ. An important part of any cost-ofillness study is to make a judgement of how well these Ôaccounting costsÕ reflect the true opportunity cost.
The methodology used in the cost-of-illness studies is briefly discussed below and more extensively in previous publications (Hodgson and Meiners, 1982; Tolpin and Bentkover, 1983; Drummond et al., 1987) .
Cost perspective
A cost-of-illness analysis can be conducted from several different perspectives. The perspective chosen determines which costs are included in the analysis (e.g. an individual hospital, insurance company or govern- 
The societal perspective implies that all costs, whether incurred by individuals, employers, or government, should be taken into account. This is preferred since the economic theory underpinning the evaluative work in the healthcare field has focused on the social welfare function, which suggests a broad societal perspective. A second reason is that brain disorders have impacts across a wide range of personal dimensions (e.g. one's health, quality of life, ability to work, social relations, income) and hence it would be falsely constraining to only look at the healthcare consequences. Thirdly, the boundaries around healthcare are different between countries so that what is called healthcare in one system is called social care in another system and consistency of estimation would require a comprehensive measure. It is also consistent with a social perspective on health and health care. Direct healthcare costs are costs for goods and services used in the prevention, diagnosis, treatment and rehabilitation of the illness, disease or disorder in question, e.g. costs for medical visits, hospitalization and pharmaceuticals. Direct non-medical costs include all other resource use related to a disease, for example transportation, social services, adaptations of accommodations etc. Sometimes it can be difficult to decide if a specific cost item, for example informal care, should be included as healthcare cost or non-medical costs. From a societal perspective, it does not matter as long as it is included in the analysis.
Indirect costs are defined as the value of the output that is lost because people with a certain illness, disease or disorder are impaired and too ill to work, either short-term or long-term (Luce and Elixhauser, 1990) . There are two main valuation methods for indirect costs: the friction method and the human capital approach. In this study the latter method was applied.
Typical cost items in this category are costs of loss of production due to short-term absence from work and from early retirement. Sometimes also reduced productivity at work due to illness, for example as a consequence Note. Purchasing power parity (PPP) is an international measure to be able to compare economic data between countries by adjusting for the relative purchasing power in the respective countries. Gross domestic product is a measure of the total national income in a country.
of depression, is included as well. The loss of production associated with disability is valued using gross earnings lost or some proportion of the gross earnings if an individual is unable to work at full capacity (Hodgson and Meiners, 1982; Luce and Elixhauser, 1990) . Sometimes lost production due to premature mortality is included in the analysis as well.
There are also intangible costs, which include pain, psychosocial suffering, and changes in social functioning and activities of daily living. Intangible costs are in general not included in currently available cost of illness studies due to difficulties in quantifying these costs. However, the intangible costs are probably far from insignificant for many diseases, and may often be dominating. These costs can be valued as DALYs or quality-adjusted life-years (QALYs) lost.
Top-down versus bottom-up approach
The top-down approach to cost estimation means that the total national costs for illnesses are divided between different diseases according to main diagnosis. In the bottom-up approach, data are collected directly from a sample of patients with a defined disease, and the figures from the sample are extrapolated to represent the whole population by using national prevalence figures.
The advantage of using the top-down approach is that no extrapolation is needed and that it avoids the risk of double counting. The disadvantage compared with the bottom-up approach is that diagnoses may be underreported or misreported and that important cost items are missing from the national illness registers. For example, costs for social services or unpaid home help are unaccounted for if a pure top-down approach is used as such resource use is not registered according to diagnosis. The value of informal care as a consequence of disease is also missing from a top-down approach to cost-of-illness studies. For mortality and disability pensions granted, a main diagnosis (but not other diagnoses) is registered in most cases. For short-term illness statistics are normally very deficient.
The current study is mainly based on the bottom-up approach, where the cost data are collected per patient and disease and aggregated to national levels with the help of prevalence data.
Prevalence-and incidence-based cost estimates Cost of illness studies can be performed by using either prevalence or incidence-based methods (Hodgson and Meiners, 1982) . Prevalence based studies examine costs incurred during a given time-period, usually 1 year, regardless of the date of the onset of disease. Incidencebased studies examine costs for cases of the disease that develop for the first time in that year. Future costs and production losses are then estimated for the entire lifetime of these patients and calculated in terms of present values. As incidence-based studies can be used for calculating the economic benefits of reducing the number of new cases, they are suitable for evaluating preventive measures (Henriksson et al., 2001) . A longitudinal analysis has the advantage of taking account of the temporal aspects of the disease, but it may be logistically difficult to follow patients over many years.
The prevalence approach has the advantage of producing cost estimates which present the annual costs for a disease in a given year and thus is comparable with the total annual costs for other, or all, diseases. If cost control is the primary concern, the prevalence approach is preferred, as the main components of current spending and lost resources (indirect costs) are identified and can be subject to savings efforts. In the present study prevalence based cost estimates were conducted as the goal was to give a broad overview of the cost of brain disorders in Europe, and to be able to compare with the cost of other disease areas as well as with national accounts.
Scope of study
The following 12 major disease areas of the brain are included in the present study: addiction (alcohol and illicit drugs), affective disorders (depression and bipolar I and II), anxiety disorders [panic disorders with and without agoraphobia, phobias (agoraphobia without panic, social phobia, specific phobias), generalized anxiety disorder (GAD) and obsessive compulsive disorder (OCD)], brain tumour, dementia, epilepsy, migraine and other headaches, multiple sclerosis, Parkinson's disease, psychotic disorders (schizophrenia), stroke and trauma (traumatic brain injury). In the presentation of results the following disease categories shall be used: neurological diseases [dementia, epilepsy, migraine and other headaches, multiple sclerosis (MS), Parkinson's disease, stroke], neurosurgical diseases (brain tumour, traumatic brain injury) and mental disorders (addiction, anxiety disorders, affective disorders, dementia and psychotic disorder). The reason for categorizing dementia into both neurological diseases and mental disorders is due to the fact that it is considered to belong to both fields in the research community. As a compromise, 50% of the specific results in dementia are referred to neurological diseases and 50% to the mental disorders. As a consequence of limiting the study to the 12 major disorders of the brain, we omit less prevalent or less homogeneous groups of brain disorders from our cost results. Hence, the total cost of all brain disorders can be expected to be much higher than the results presented in this study.
Cost of disorders of the brain in Europe
The geographical scope is set to the 25 European member states (by 2004) plus Iceland, Norway and Switzerland.
Health economic model
The model deployed for this study aims at assessing the cost of illness for Europe with the help of three major sources of data: economic data, epidemiology data and international statistical data. The model was also used to predict results for countries where no input data were available in the literature. The economic model is depicted in Fig. 2 .
As the model is based on available epidemiology and economic data from the individual brain disorders included in the study, there is an inherent problem of double counting (see Top-down versus bottom-up approach).
This problem stems less from the economic data, as they measure the cost for a specific brain disorder rather than the cost for a patient with the disease. In the epidemiologic data, however, which are determined by individual brain disorder, the problem of comorbidity becomes critical. Diseases are added to form an aggregated estimate for brain disorders in total (e.g. patients with dementia probably also have depression and hence are double-counted in the cost calculations). The issue of comorbidity is most apparent within the mental disorders, where multiple diagnoses are common (e.g. anxiety disorders and addiction). Hence, this problem might result in an over-estimation of the total number of patients with brain disorders in Europe and consequently may inflate the total cost estimates of brain disorders in Europe. The health economic model described in Fig. 2 is explained in detail in the following. The model serves four major purposes:
1 Time transformation of economic data. The cost data collected from the literature are reported from different years for which they were originally costed. In order to be able to compare the price tags (cost per patient) across nations, it is necessary to transform the data to a common year. The year chosen for the study is 2004. There are several measures for inflating cost estimates. The measure chosen for the present study was the consumer price index (inflation), which is an aggregate measure of the increase in the consumer prices for a predefined basket of goods and services in the specific country. A health-specific price index could also serve as an appropriate inflator, but no international statistics were obtained covering all European countries selected for this study. 2 Adjustment for international comparison. The data collected for the study are reported in different currencies, and consequently influenced by the price level existing in the specific country, from where the estimate origins. In order to be able to compare the cost estimates across Europe, the collected cost data were adjusted for the differences in purchasing power. Purchasing power parity adjusted currency rates were therefore used and all results were converted to Euro (€PPP). 3 Imputation of data. For countries in Europe where no cost data were available, the model was developed to impute cost estimates based on the available input data. An average of the selected economic input data was calculated and formed the basis for imputation. The imputation used different algorithms which were based on indexes from international statistics to eliminate the price level differences across Europe. Healthcare cost data were imputed with an index on price level differences in the healthcare sector in Europe, direct nonmedical cost data (e.g. transportation, adaptations due to disease, etc.) were imputed with an index on price level differences in the whole economy of European nations (national income), the drug cost data were imputed with an index on price level differences in the pharmaceutical sector and, lastly the indirect cost data were imputed with an index based on wage level differences in Europe. As a base case, the indexes applied were based on purchasing power parity statistics. Sensitivity analyses were conducted based on indexes presented in nominal values, real values and real values with purchasing power parity adjustment. 4 Assessing the cost of illness in Europe. The final step in the model is to combine the two data sets in order to estimate the cost of illness in Europe. Hence, the cost data were aggregated to national levels with the help of prevalence data for each European country and the estimates for each country were added to yield an aggregated European cost estimate. 
Model validation
The health economic model was tested for its validity in two ways: sensitivity analysis on critical assumptions made in the model (internal validity) and the base case cost estimates were compared with previous cost estimates in brain disorders (external validity). Cost results were compared with previous European and American studies in the field.
Results

Total prevalence
The total number of people with any brain disorder in Europe amounted to 127 million in 2004, corresponding to 27% of the total number of inhabitants in the European countries covered by this study. The total prevalence of brain disorders is an aggregate of the prevalence estimation for each brain disorder included in the study. However, the prevalence estimates in mental disorders, migraine and epilepsy are all based on the European patient populations aged 18-65 years. The estimates in dementia and Parkinson's disease are limited to the population aged 65 years or older, and stroke on the age group 25 years or older.
Total numbers of cases with addiction in Europe totalled 9 million (including illicit drug dependence and alcohol dependence). If we were to add nicotine dependence to this estimate the total amount of cases would be 37 million. Affective disorders (depression and bipolar disorders) and anxiety disorders (panic, phobias, OCD and GAD) resulted in 21 4 and 41 million cases in Europe respectively. The most prevalent neurological brain disorder is migraine, with an estimated 41 million cases in Europe. Distribution of the total number of estimated cases with brain disorders in Europe across specific disorders are presented in Fig. 3 . Amongst the less prevalent brain disorders multiple sclerosis and brain tumour have an estimated 380 000 and 135 000 cases, respectively.
As cases of specific brain disorders were added to an aggregate estimate for Europe, there is an expected overestimation. Due to comorbidity both within disorders (e.g. anxiety disorders) and between neurological and mental disorders, e.g. multiple sclerosis and depression, the number of persons with a brain disorder is smaller than the estimated prevalence. Assuming a comorbidity between neurological and mental disorder of 31.6% 5 , the total number of persons with brain disorders in Europe would be the order of 104 million.
It should be noted that the number of cases calculated for stroke and trauma were based on incidence data rather than prevalence data, and it is expected that the number of cases are underestimated relative to other disorders of the brain.
In Table 4 , it should be noted that there are significant differences in the number of cases of disorders of the brain in different European countries, which mainly reflects the size of the population. The relative prevalence of any brain disorder across Europe (i.e. proportion between number of cases of brain disorders and total population) is shown graphically in Fig. 4 . The frequency of brain disorders ranges from 19 to 36% (note that these numbers are not adjusted for comorbidities between brain disorders). Interestingly, some northern European countries (The Netherlands, Norway, Sweden and Germany) have the highest prevalence of brain disorders, whereas southern European countries (France, Italy and Spain) have lower prevalences. Given the considerable heterogeneity of methods, the consistency of prevalence estimates for all brain disorders is striking. It is beyond our ability to decide whether the differences between countries are true or simply results of slightly different assessment strategies and design to estimate the prevalence. The number of cases of stroke and trauma are based on incidence data in the lack of appropriate prevalence data in the literature. Results on addiction omit nicotine dependence and abuse. 4 This estimate refers to adults (age 18-65). Assuming the same prevalence for younger (<18) and older (>65) populations, the estimate would be 32 million cases in Europe.
5
Estimate from the German Health Examination Survey (Jacobi et al., 2002; Wittchen et al., 2000) . Prevalence data were based on population aged 25 or older.
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Note: The total number of cases in stroke and trauma are based on incidence data and hence are expected to be underestimated relative to other disorders of the brain.
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Cost per patient
The economic input data were calculated in terms of cost per case of each specific brain disorder. For countries where no input data were available, cost data were imputed using indexes which adjusted for price level differences across countries in Europe. The estimated cost per case is displayed by country and by brain disorder in Table 5 . The cost per case differs significantly across the specific disorders of the brain, ranging from €133-1030 per case of migraine in Europe to €9000-68 000 per case of brain tumour in Europe. Our estimates show that the cost per case of brain disorder differs between countries and are highest in countries with the highest national income and healthcare expenditure per capita. This explains the estimated lower costs per case in the EU admission countries. The less prevalent disorders of the brain have a higher cost per case, e.g. brain tumour and multiple sclerosis. Figure 5 presents the average cost per case in each brain disorder. Brain tumour has an average cost per case of €39 000 across Europe. Multiple sclerosis has a slightly lower cost per case, with an average in Europe reaching €24 000. These cost estimates are weighed averages across Europe, see Table 5 . Addiction, anxiety disorder and migraine have the lowest average cost per case: €1700, 800 and 600, respectively. However, it should be emphasized that there is a considerable degree of uncertainty. Regarding the precision of such estimate -both with regard to the disorders specific total cost as well as the respective estimations for each country.
Therefore, it should be noted that direct comparison of cost results between disorders of the brain are difficult to make, due to scarce data. For instance, the cost per case of trauma is only based on cost of hospitalization, and hence omits both rehabilitation and costs due to lost workdays.
Total cost of brain disorders
The total cost of all brain disorders was estimated at €386 billion in 2004 in Europe (see Table 6 ). However, it should be remembered that this is a conservative estimate as: (i) not all brain disorders are included in the estimate, (ii) not all costs are included for some disorders and (iii) prevalence estimates for some disorders do not cover the whole population.
The cost of nicotine dependence was not included in the final cost estimate of brain disorders in Europe, due to the restricted scope in this study. Moreover, most cost studies on smoking concentrate on smoking in general, which is too broad a category to include under addiction. Nevertheless, the cost of nicotine dependence amounted to another €15 billion. Another specific brain disorder where a major cost component is omitted is for non-migraine headaches, as there is no economic evidence available for these in Europe. However, estimating the cost of other headaches based on American cost data would suggest an additional cost of €46 billion in addition to migraine. Including these two estimates to the total cost of disorders of the brain in Europe, it would total €447 billion. The cost of stroke is, moreover, expected to be underestimated, due to scarcity of good prevalence data and follow-up data on cost of stroke after the 1 year with stroke. In addition, several other costs are missing and shown in detail in Table 2 .
As can be observed in Table 7 , the total cost of disorders of the brain is unevenly distributed across European countries in absolute terms. This is due to differences both in size of the European economies as well as differences in populations. Seventy per cent of the total cost of brain disorders is attributable to the five major countries in Europe (Germany, UK, France, Spain and Italy). The same countries hold 64% of the total population in Europe. The cost of brain disorders varies substantially from one European country to another. There are two reasons for the difference: difference in the prevalence of brain disorders (which was observed earlier) and differences in the cost per case of brain disorder. Table 7 shows the distribution of the total cost. The indirect costs are almost twice as big as the direct costs. The direct healthcare costs are almost twice as big as the direct non-medical costs.
Cost of brain disorders per inhabitant
The average cost of brain disorders in Europe was €829 per inhabitant (based on a total number of inhabitants Cost of disorders of the brain in Europe in Europe of 466 million). Figure 6 shows the difference in cost of brain disorders per inhabitant between European countries. The cost of brain disorders per inhabitant is higher in western European countries compared with the EU admission countries. This can be due to either higher prevalence numbers in western Europe or higher costs per case. The comparison of the cost of brain disorders per inhabitant in different European countries should be taken with caution. The economic input data are scarce in some areas of brain disorders and often depending on estimates for one single country. Furthermore differences in results are driven by the assumptions made in the cost estimation model and, thus, depend on the national statistics presented in Table 3 . For instance, indirect cost estimates are imputed with the relative wage difference (adjusted for purchasing power) in European countries. The wage statistics in Table 3 , explained for instance the difference in cost results obtained for Germany, UK and France. Moreover, there are substantial differences in the prevalence of certain brain disorders between countries in Europe, which heavily influences the differences in the cost per inhabitant of brain disorders.
Cost of brain disorders distributed by resource items
The distribution of the total annual cost of brain disorders in Europe on different resource items is presented in Fig. 7 . Direct healthcare cost due to brain disorders in Europe (i.e. cost of hospital care, drugs and outpatient visits) amounted to €135 billion, corresponding to 35% of the total cost. The cost for hospital care is the dominating healthcare cost, reaching €78 billion in 2004 (20% of the total cost and 57% of the healthcare cost). The cost of outpatient care amounted to a total of €45 billion, making up 12% of the total cost of disorders of the brain. Drug cost totalled €13 billion (3% of the total cost). However, it should be noted that this cost estimate relies on cost data originating from the 1990s or at best beginning of 2000. The cost patterns have radically changed in many disorders of the brain (e.g. Parkinson's disease and multiple sclerosis), where new treatments have been introduced. However, it can be expected that the increased cost of treatments is offset by reduction in other healthcare resource utilization (e.g. hospital care) and these effects thus may equal out. Direct non-medical costs (i.e. community care, transportation, adaptations and informal care) totalled €72 billion in Europe. The largest non-medical resource component was cost of social services due to brain disorders, amounting to €52 billion (13% of total cost). Informal care was only estimated for dementia and multiple sclerosis, but for these disorders it totalled €13 billion (corresponding to 3% of the total cost). The cost of adaptations and transportation (other costs) was €8 billion (2% of the total cost). However, it should be noted that direct non-medical cost was not estimated at all in several disorders of the brain (cf. Table 2 ). Hence the total direct non-medical cost due to brain disorders is conservatively estimated.
The bulk of the cost of disorders of the brain in Europe was due to lost workdays and production (indirect costs). The indirect cost was estimated to €179 billion, 46% of the total cost. The majority of the indirect cost of brain disorders was caused by sick leave, €124 billion (33% of the total cost). The cost of lost workdays due to early retirement and premature death each amounted to €27 billion.
An important direct non-medical cost, which was not included in our study, is cost due to criminal activity caused by brain disorders. Mental disorders such as addiction and psychotic disorder frequently cause criminal activity. We have chosen not to include these estimates in the base case results. However, we have dedicated a later section to this issue based on research conducted in addiction (see the section Cost of crime in estimates of the cost of addiction in Europe).
We also allowed dividing our results by the three main specialties: neurological, neurosurgical and psychiatric disorders (see Fig. 8 ). In the neurological diseases, the direct cost is the dominating resource, comprising 63% of the total cost. In the neurosurgical diseases (brain tumour and trauma) indirect costs are predominant, making up 42% of the total cost. A similar distribution of the cost of mental disorders can be observed, where indirect costs make up 50% of the total cost. Cost of disorders of the brain in Europe Cost of brain disorders distributed by medical speciality and specific brain disorder
The total cost of brain disorders is an aggregated result of the 12 most prevalent disorders. It has already been observed that both the cost per case of specific brain disorders and the total number of cases with the different brain disorders differ substantially. Consequently, it is also expected that the aggregated cost result differs from one brain disorder to another. Mental disorders amounted to €240 billion and hence constitute 62% of the total cost (excluding dementia), followed by neurological diseases (excluding dementia) totalling €84 billion (22%). Neurosurgical diseases made up a smaller fraction of the total cost of brain disorders in Europe, reaching a cost of €8 billion. Dementia, which is considered both a mental disorder and a neurological disease amounted to €55 billion.
Amongst the mental disorders, the cost of affective disorders (depression and bipolar disorders) was the highest, with a total of €106 billion, followed by addiction (drug and alcohol dependence), €57 billion (cf. Table 8 ). The cost of anxiety disorders amounted to €41 billion, whereas psychotic disorder (schizophrenia) reached a total cost of €35 billion. However, it should be noted that the cost of anxiety disorders and affective disorders did not include direct non-medical cost, and that the indirect cost due to anxiety disorders only comprised lost workdays due to sick leave. Moreover, in psychotic disorder, no cost data were included which covers indirect cost due to schizophrenia, which is expected to make up a substantial economic burden to society.
In the neurological diseases included in the study, migraine was estimated to cost European society a total of €27 billion. The second most costly neurological disease was stroke, totalling €22 billion, followed by epilepsy, Parkinson's disease and multiple sclerosis with costs of €16, 11 and €9 billion, respectively. The cost of stroke is, however, expected to be heavily underestimated, as it is based on incidencebased cost estimations (due to the lack of both appropriate cost data and prevalence data in the literature).
Two neurosurgical diseases were included: brain tumour and trauma (traumatic brain injury). The cost of brain tumour in Europe amounted to €5 billion and traumatic brain injury reached a total cost of €3 billion. The cost estimation of trauma is, however, expected to be grossly underestimated. It is only based on the hospitalization costs due to trauma, and hence omitting both rehabilitation costs and costs due to lost workdays and production. Moreover, the estimate is based on 12-month incidence data instead of prevalence data (due to lack of appropriate prevalence data in the literature). A very loose guess is that indirect costs of trauma are probably in the order of €10-20 billion.
Results on specific dimensions in brain disorders in Europe
The results presented earlier were all reported on aggregated levels without focus on specific dimensions in the costing of disorders of the brain. In the following a couple of examples will be given from specific brain disorders.
Cost of crime in estimates of the cost of addiction in Europe
The cost of crime has become an increasingly important factor for governments and other decisionmakers who are concerned with the impact of crime on economy and society in general. However, there Note: Differences in cost of brain disorders between countries in Europe are dependent on the national statistics applied in the model imputations of cost estimates to countries where no data was available (see Table 3 ), and variations in the prevalence of brain disorders.
Cost of disorders of the brain in Europe are methodological challenges, not only in valuing the resources used for crime-related activities due to a disorder, but also to identify and quantify the resource use. Nevertheless, in addiction there are several studies conducted attempting to estimate the cost of alcohol and illicit drug related crime in society. This cost component was not included in the base case estimation of the cost of addiction in Europe reported earlier, as there are still too few studies to judge on the methodological appropriateness. Yet, attempting to estimate the cost of crime due to addiction in Europe, may give an impression of its impact on society.
In the estimation of the cost of crime-related activities due to alcohol dependence, the following resources were included: alcohol-related costs to the criminal justice system, costs due to alcohol-related property and victim services and lost productivity to victim, drink driving related costs (criminal justice system, lost productivity and medical resources to drink-driving casualties). In illicit drug use the crime-related resources were concentrated to the cost of victim and criminal justice system due to burglary, robbery, shoplifting and vehicle theft.
The total cost of addiction totalled €57 billion in Europe, excluding the cost of crime. When estimating the crime-related resources due to alcohol and drug dependence, an additional cost of €53 billion is estimated. Hence, the total cost of addiction would reach a total cost of €110 billion, which is almost doubling the total cost of addiction to the European society. Yet, this result is expected to be conservative when comparing with specific studies conducted for individual European countries. Still, there is little research conducted on the cost of crime related to illness and hence further research is needed to validate the appropriateness of the principles and valuation methods applied here. Figure 6 Total cost of brain disorders in Europe by country standardized for population size (€PPP/capita) Note: The total annual cost of brain disorders was divided by total population in each country. Direct non-medical costs are missing for the following disorders: affective disorders, anxiety disorders, migraine and trauma. 
Informal care in dementia in Europe
Informal care is the unpaid care provided by family members, friends or voluntary workers to disabled and impaired individuals in the community. Most disabled elderly persons benefit from informal care to some degree, and many families choose informal care over formal, paid care. This is especially true for those European countries where there is a tradition of caring for the elderly at home. The majority of brain disorders have a disabling effect on the patient to the extent that care is needed. Moreover, the chronic nature of most brain disorders means that informal care is needed over a long period of time. Nevertheless, it is difficult to find appropriate cost estimates for informal care in brain disorders in the European literature. We were only able to cost informal care in multiple sclerosis and dementia.
The total annual cost of dementia was estimated at €55 billion in Europe. Twenty per cent of the total cost was attributable to informal care, corresponding to €11 billion (see Fig. 9 ). Hence, the total cost of informal care almost equals the total healthcare cost attributable to dementia in Europe. In these estimations the informal care costs were evaluated by measuring the time spent on care of the demented patient, valued as would care be given to a professional care-giver. This valuation principle is, however, still debated and the cost estimates vary according to the principle applied.
Multiple sclerosis -a brain disorder with comparably good data coverage in Europe Multiple sclerosis is the brain disorder, for where we have the best availability of epidemiologic and economic evidence in Europe. In the following, we present the specific cost estimation results for multiple sclerosis in Europe. This can serve as an example of how the uncertainty in the final cost estimates Cost of disorders of the brain in Europe decrease with improved availability of epidemiologic and economic input data. The input data for the cost estimation for multiple sclerosis have been described in more detail in previous publications (Kobelt, 2004; Pugliatti et al., 2005) .
Cost per patient and prevalence in multiple sclerosis. The total cost per patient ranged from €7000 to 41 000 in 2004 across Europe, with a mean cost per patient of €23 695 (cf. Fig. 10 ). The total cost is fairly evenly distributed between direct healthcare, direct nonmedical (including informal care) and indirect costs. The total amount of patients with multiple sclerosis was estimated at 380 000 in Europe. The point prevalence varied from 17 to 154 cases per 100 000 inhabitants across Europe.
Cost of multiple sclerosis in Europe. The total cost of multiple sclerosis was estimated at €8.8 billion in Europe in 2004 (Table 9 ). The total direct cost constituted 50% of the total cost and social services was the largest single cost component. Cost of informal care (e.g. family) was estimated at €1.8 billion and make up one-fifth of the total cost. The indirect costs were dominated by the cost of lost workdays due to early retirement. The cost of drugs amounted to €462 million, and is expected to be grossly underestimated for 2004, because of new treatments that were introduced in the beginning of this decade.
The results provided so far are based on pure resource consumption and on reduced or lost working ability. However, these results exclude intangible cost due to the psychological burden and stress of the disease. As MS is a chronic disease with a relatively early onset (around 40 years on average), the intangibles are expected to be substantial. One way of measuring this is to compare the patientsÕ self-rated quality-of-life scores at each level of severity of disease to the scores by the normal population (Raisch, 2000) . The difference in quality-of-life can thus be used as a proxy to calculate the loss of QALY (Torrance, 1986 1998). The average reduction in quality-of-life in patients with MS is in the range of 0.30-0.5 compared with the normal population (Kobelt et al., 2000 (Kobelt et al., , 2001 . By assigning a value to (or willingness to pay for) a QALY, the intangible cost due to MS can be estimated. There is no agreed value for a QALY in Europe, and to assure a conservative, estimate the value was set to GDP/capita in Europe (Eichler et al., 2004) 6 . The intangible costs due to multiple sclerosis in Europe were thus estimated to €4.2 billion. Hence, by estimating the total economic burden of multiple sclerosis in Europe, the total cost is at least €13.0 billion for 2004.
Stratification of results by gender and disability level. The prevalence of multiple sclerosis is higher in women than men. When stratifying our total cost estimate by gender, 70% of the total cost of multiple sclerosis is attributable to women with MS, corresponding to €6.1 billion.
A generally accepted way of stratifying patients according to severity of multiple sclerosis is by the Expanded Disability Status Score (EDSS) (Kurtzke, 1955 (Kurtzke, , 1983 . The prevalence data and cost data were stratified according to the EDSS-scale in three groups: mild (EDSS score: 0-3/3.5), moderate (EDSS scores: 3.5/4-6.0/6.5) and severe (EDSS score: 6.5+). Figure 11 shows how the cost per patient increases with increased disease severity, being €9178 in the mild cases and €39 722 in severe cases. Consequently, the cost per patient is four times higher in severe cases of MS compared with milder forms.
Milder forms of multiple sclerosis (EDSS score: 0-3/ 3.5) are, however, more than double as prevalent as severe cases. Thus, at an aggregated level, the total cost of mild cases of multiple sclerosis in Europe were €4.8 billion, corresponding to 54% of the total cost, whereas the cost of moderately and severe cases of multiple sclerosis were €2.1 billion (24%) and €1.9 billion (22%), respectively.
Our findings show not only that MS has a significant impact on the national healthcare budgets in Europe, but also that it has substantial costs to social services and non-paid caregivers (informal care). As MS has a relatively early onset in life and is a highly disabling disease, there is also a high proportion of patients who stop working due to the disease. Earlier studies from individual European countries confirm the distribution of the cost of MS between care within and outside the healthcare sector (O'Brien, 1987; Holmes et al., 1995; Blumhardt and Wood, 1996; Midgard et al., 1996; Henriksson and Jo¨nsson, 1998; Kobelt et al., 2000; Henriksson et al., 2001; Amato et al., 2002) . There are no previously published studies estimating the total cost of MS in Europe in the literature. However, an American study estimated the total cost of MS in the US to $8.3 billion [scaled to 2004 with the US inflation (US Census, 2005)] (Grudzinski et al., 1999) . Considering a higher number of MS cases in Europe and the US study being a 10 years old estimate our results can be regarded as conservative. When comparing our results with selected previous publications which were not included in the cost calculations (Midgard et al., 1996; Carton et al., 1998; Murphy et al., 1998; Rubio-Terres et al., 2003) , there is a relatively good coherence in the final estimates (see Table 10 ). 6 There has been a suggested valuation principle for the willingness to pay for the gain of a QALY set to three times the GDP per capita (WHO, 2001) . However, there are currently discussions Europe on establishing a threshold value lower than what this principle would result in.
Cost of disorders of the brain in Europe
The intangible cost of all brain disorders could have been estimated similarly to that of multiple sclerosis. This was, however, not done due to lack of appropriate QALY data in many fields. Moreover, the principle of adding the intangible costs to the conventional cost estimates for an illness is still debated due to possible double-counting.
Sensitivity analysis and validation of results
Two types of sensitivity analyses are employed to test the validity of the results obtained: (i) tests of internal validity and (ii) tests of external validity. The internal validation aims at testing the sensitivity in the key input parameters used in the cost estimations. The external validity tests aim at benchmarking our results with previous study results in the literature and compare the reasonability in our results compared with European statistics. It thus validates the generalizability of our results.
Internal validity
The key input parameters that were tested for are: (i) 12-month prevalence (or incidence) data employed, (ii) estimated cost data used and (iii) the indexes used for imputation of cost data.
The prevalence and incidence data used in the cost estimations in this study were decreased and increased by 10%. The total cost of brain disorders varied between €347 and 424 billion (see Table 11 ). Moreover, due to the expected comorbidities between brain disorders in Europe, a sensitivity analysis was conducted by adjusting the prevalence input data. An estimated comorbidity of 31.6% between neurological and mental disorders was applied, based on a database analysis from the German GHS-MHS survey (Wittchen et al., 2000; Jacobi et al., 2002 Jacobi et al., , 2004 . The adjustment for comorbidity resulted in a total cost estimate of €309 billion.
The estimated cost data (presented as cost per patient) were varied in a similar way as the prevalence data. The results were estimated at €347 and 424 billion.
A two-way sensitivity analysis was conducted based on the prevalence and cost data in a specific brain disorder: anxiety disorders. This was made possible as the cost data in anxiety disorders was estimated with help of primary data analysis based on the German National Interview and Examination Survey (Wittchen et al., 2000; Jacobi et al., 2002 Jacobi et al., , 2004 ). An aggregated cost per patient with anxiety disorders was estimated. Similarly, an estimated 12% 12-month prevalence in anxiety disorders was employed based on findings from the same German survey (Wittchen et al., 2000; Jacobi et al., 2002 Jacobi et al., , 2004 . The sensitivity analyses resulted in an estimated cost of anxiety disorder in Europe of €20 billion (compared with the non-adjusted estimate of €41 billion). Consequently the total cost of brain disorders in Europe, when adjusted for the effect of comorbidities in anxiety disorders, reaches an estimate of €347 billion (compared with €386 billion in base case; cf. Table 11) .
Cost data were imputed with indexes based on national statistics (relative national income, healthcare expenditure, drug expenditure and wages). In the base 31.6% comorbidity assumed between neurological diseases and mental disorders (based on comorbidity data from the German GHS-MHS Survey (Jacobi et al. 2002 (Jacobi et al. , 2004 Wittchen et al. 2000) ).
2 Adjustments made for anxiety disorders, with one single aggregated prevalence estimate for all anxiety disorders (12-prevalence estimate of 12% based on the GHS-MHS Survey) and pooled resource use data for all anxiety disorders. Data was then extrapolated to all European countries.
case estimations the national statistics were adjusted for purchasing power differences between countries in Europe. For sensitivity analyses the following alternative adjustments in the indexes were tested for: (i) statistics based on nominal values, (ii) statistics presented in real values, and (iii) PPP adjusted statistics presented in real terms. The total cost of brain disorders varied from €370 to 383 billion, compared with the base case estimate of €386 billion. In addition, a sensitivity analysis was conducted employing the imputation based on only one national statistic: (i) purchasing power adjusted healthcare expenditure and (ii) purchasing power adjusted national income statistics. The results obtained were higher than the base case, and varied between €397 and 422.
External validity
The external validity was tested by comparing our results with European national statistics in order to verify the reliability in the results obtained. Moreover, results by country and brain disorder were compared with earlier study results from the literature. A German cost-of-illness study (Statistisches-Bundesamt, 2004 ) served as a benchmark. Moreover, our results were compared with previous findings in the American literature. The total healthcare expenditure was estimated to €923 billion in Europe (Eurostat, 2004a) . The total healthcare cost of disorders of the brain was estimated at €135 billion, and hence corresponding to 15% of the healthcare budgets in Europe (see Table 12 ).
In a similar comparison, the drug cost due to brain disorders comprises 8% of the total sales of drugs in Europe (corresponding to €290 billion in Europe). However, it should be noted that the drug cost attributable to brain disorders in Europe is based on data mainly originating from the 1990s and thus do not reflect the drug use in 2004. Finally, when relating the total cost of brain disorders in Europe to the total national incomes in Europe, a proportion of 4% is reached (total national income in Europe is estimated to be €10 382 billion).
No previous study has estimated the total cost of brain disorders in Europe. However, in order to compare our results with European data, a comparison was made with a recent German cost-of-illness study conducted by the Federal Statistics Office in Germany (Statistisches-Bundesamt, 2004) . Six areas of brain disorders were possible to compare (due to a different grouping of diseases in the German study): dementia, epilepsy, migraine and other headaches, affective disorders, anxiety disorders and psychotic disorders. The estimates in neurological diseases obtained in our study overall comparable with the findings in the German study (cf. Table 13 ).
In psychotic disorders our result is much higher than in the German study, most probably due to differences in methodology, where the input data for our model is based on the European EPSILON study (Knapp et al., 2002) , bottom-up cost-of-illness study with a detailed inclusion of healthcare resource use, whereas the German benchmark study is based on a top-down approach and national healthcare statistics. As was discussed in the previous section Top-down versus bottom-up approach, there is a possibility of under inclusion of resource utilization.
Our results were furthermore compared with previous cost-of-illness studies conducted in the US. The results of the comparison are summarized in Table 14 .
In the neurological diseases, there seems to be a good coherence between our results compared with previous findings in the American literature. The only area where our results are lower is in trauma. This confirms our expectations, as our cost estimate of trauma in Europe is only based on cost data on hospital care, and hence omits other direct and indirect costs. Moreover, it is based on 12-month incidence data, which is expected to be lower than the 12-month prevalence in trauma. (Eurostat Yearbook 2004) .
Cost of disorders of the brain in Europe
In the area of mental disorders, the American literature reports similar estimates in anxiety disorders and psychotic disorders. The cost of affective disorders was estimated lower in the US. However, the results originate from cost of illness studies conducted at the beginning of the 1990s. Hence differences can be explained by improvements in methodology over time. Moreover, addiction was estimated at a lower level in Europe than in the US. However, it should also be noted that the American cost studies are based on the full population sizes, whereas our estimates are, in part, restricted to the adult population only.
Discussion Final results and uncertainty
The results from the present study show that brain disorders cause a substantial economic burden to healthcare systems, community, other caregivers and the wider society. The distribution of our total cost estimate of brain disorders in Europe confirms the expectations, that the majority of the costs are identified outside the formal healthcare sector. These are primarily due to reduced productivity during years of employment and to pre-mature retirement (caused by both morbidity and mortality). The indirect costs were dominant cost components, particularly in mental disorders. Furthermore, our results highlight the heavy reliance on community care as well as informal care (family and other caregivers) in brain disorders, especially in neurological diseases. The total cost of brain disorders is highly skewed to the western European countries (standardized results for population size), whereas the new EU admission countries bear a minor part of the cost, probably due to both the quantity of health services offered as well a as the price of the same. Available data does not make it possible to separate these two effects in detail. The results presented in this study are, however, attached with uncertainty. In the following the results from the sensitivity analyses shall be discussed.
External validity
The external validation of our results shows that they are in relatively strong concordance with previous research findings in the literature. Previous studies from the USA confirm the results achieved in specific brain disorders included in our study as well as the relative cost between the same (Hay and Ernst, 1987; Huang et al., 1988; OTA (Office of Technology Assessment), 1988; Schneider and Guralnik, 1990; Manton et al., 1993; Ernst and Hay, 1994) . The comparison indicated possible underestimations in mental disorders, e.g. anxiety disorders. This is somewhat expected, as the cost input data applied in anxiety disorders are underinclusive. Moreover, the comparison of the cost of trauma confirmed that our result substantially underestimate the true economic burden of the disease. However, there is no earlier comprehensive European cost-of-illness study in brain disorders, it was difficult to say anything about the validity of our results in relation to other studies. Studies for specific diseases, in a specific country at a specific point in time can be used to validate the estimates, but not the overall result. Thus, further research is necessary to validate the results of this study.
Internal validity
The internal validity of the cost estimation model showed little uncertainty concerning the imputation (Ernst & Hay 1994; Hay & Ernst 1987; Huang et al. 1985; Manton et al. 1993; Schneider & Guralnik 1990 (Holland & Mushinski 1992; Rice 1995; Rice et al. 1991) technique employed. However, as mentioned previously, the inherent challenge of double counting becomes clear in our results. The sensitivity analyses that were conducted in order to adjust for the effect of comorbidity confirm the problem (for further discussions see the section Methodological aspects). In order to investigate the uncertainty around the final cost estimates, there is a need for prospective epidemiological and economic studies specifically aimed at investigating the issue of comorbidity in brain disorders in Europe. Despite the uncertainties discussed above, the estimated cost of brain disorders in Europe of €386 billion is probably to be an underestimation due to missing data. Furthermore, the estimate is only based on the most prevalent brain disorders in Europe and excludes many important groups of diseases. Secondly, the cost coverage is far from complete in the brain disorders costed in this study. Thirdly, the cost of nicotine dependence, non-migraine headaches and crime associated to substance abuse were omitted in the base case cost estimations.
Methodological aspects
There are several methodological aspects that have been highlighted throughout our study. In this section, the most critical methodological issues are discussed further: (i) the effect of comorbidity on the cost of brain disorders in Europe and (ii) methodological issues around the epidemiologic and economic data applied.
Comorbidities
The cost-of-illness methodology was applied in the present study, using a modified bottom-up approach when estimating the cost of brain disorders: we estimated the cost per patient by specific brain disorder and country and thereafter multiplied the cost estimates with our 12-month prevalence (or incidence) and population data for each country to aggregate the results to a European level. An alternative approach would be to apply the top-down approach, estimating the proportion of the cost attributable to individual brain disorders from national statistics (e.g. health care spending). As mentioned previously (cf. under Cost-of-illness methodology), the bottom-up approach includes the risk of double counting, as there is mainly epidemiology and economic data on individual disease. There are several reasons for double counting, but the most critical one is the issue of comorbidities between disorders of the brain (see further under Sensitivity analysis and validation of results). The issue is most researched in the area of mental disorders, with estimated rates of comorbidity between mental diagnoses ranging from 44 to 94% (Jacobi et al., 2004) . There are techniques to adjust for the effect of comorbidity in epidemiology surveys (Kessler et al., 2002) . We were only able to adjust for comorbidities between the specialties in disorders of the brain, omitting the comorbidity effects between individual diagnoses. Nevertheless, our results indicated a significant reduction in the total cost of disorders of the brain when this effect was adjusted for. However, as the input data for the adjustment was based on the German National Interview and Examination Survey, the challenge remains for future research to confirm the comorbidity patterns in brain disorders all over Europe in order to better understand the full impact of comorbidities on the cost of brain disorders.
Input data
The other methodological challenge in this study concerns the economic and epidemiologic input data. The cost estimates in this study are based on a health economic model. The model predictability is, however, limited to the accuracy of the input data. The input data selected for this study were critically reviewed by groups of experts in the specific fields of disorders of the brain, in order to ensure the usage of best evidence available today. However, the lack of data, for instance in the EU admission countries, made imputations and best estimates necessary. Thus, it is difficult to verify the appropriateness of these estimates until proper field studies are conducted.
Hence, the results from our study must be interpreted in the light of these methodological limitations.
Missing data
Our cost estimates of disorders of the brain in Europe are based on the current epidemiologic and economic evidence. Our study has identified several research gaps, which have important consequences for our results.
Cost data
There was a satisfactory coverage of cost data in the major western European countries, although coverage differed substantially across the specific brain disorders and from country to country. The major gaps in terms of geographical coverage were identified in the new EU admission countries, where no single cost-of-illness study met the criteria for selection in the health economic literature review. Consequently, it is difficult to estimate the cost of brain disorders in Eastern Europe, and further studies are needed to verify the accuracy in our results.
The economic evidence in Europe was highly varying between the specific disorders of the brain. The best cost data coverage was identified in: schizophrenia, multiple sclerosis, dementia and stroke, whereas major gaps were identified for anxiety disorders, brain tumour and brain trauma. Furthermore, there is varying amount of studies within each specific brain disorder. In migraine and other headaches, for instance, headache was omitted from the total cost estimates due to lack of data, but it was suggested to be almost twice as costly as migraine (cf. in previous section Total cost of brain disorders).
The available cost data selected in the reviews were of varying quality. They had different aims, designs and study populations, which makes it difficult to combine the data for the purpose of this study. Moreover, the completeness of the selected cost-of-illness studies differed between disorders. Most selected studies included complete data on direct healthcare use, but to a lesser extent resource use outside the formal healthcare sector such as community care and direct non-medical expenses (e.g. in anxiety disorders). Our results have shown that indirect costs make up the biggest part of the cost of brain disorders in Europe. However, not all cost studies selected had complete indirect cost data (e.g. anxiety disorders, addiction, stroke and epilepsy), and some did not include it at all (e.g. schizophrenia and trauma). Our results emphasise further the importance of including valuations of cost of informal care and intangible costs in studies of brain disorders. The only brain disorders where the cost of informal care has been valued properly in Europe are dementia and multiple sclerosis. Our results show that informal care comprises more than 20% of the total cost of dementia in Europe. Our specific results on multiple sclerosis also show the impact of including intangible cost to the total estimate. It added another 50% to the conventional cost estimated for multiple sclerosis. A similar result has been obtained in previous cost-of-illness studies (Henriksson et al., 2001) .
Thus, there is a great need for further studies based on sound cost-of-illness methodology and primary data, which picks up the full range of resources associated with the particular brain disorder at study.
Epidemiologic data
The epidemiologic evidence on brain disorders in Europe is in general more conclusive than the health economic data. However, there are still major research gaps identified particularly in the EU admission countries. The best geographical coverage of epidemiologic data was identified in multiple sclerosis, epilepsy and dementia.
The methodology in the selected epidemiology studies of brain disorders is varying between specific brain disorders and across European countries. Few studies are prospective in their design and include a broad study population.
The epidemiologic evidence in brain disorders is, moreover, scarce in the youngest and oldest population groups. In mental disorders, no studies were selected including prevalence estimates of specific diagnoses in the age groups below 18 and above 65. Thus, the omission of possible cases of brain disorders outside the age range results in an underestimation of the cost of brain disorders for the whole population in Europe.
Our cost estimations were based on 12-month prevalence data for most brain disorders, with the exception of stroke and trauma where incidence data were employed instead (due to scarce prevalence data in Europe). However, we know that incidence data serve as bad proxy for the true prevalence of stroke and trauma and hence underestimates the number of cases of these disorders significantly (see previous section Total prevalence). Partly this is corrected for by adjusting the cost per case estimate to the measure of the number of cases. Thus, in relation to other major disease areas, brain disorders seem be most costly to society. Nevertheless, the present study strongly indicates the need for further research in brain disorders both in terms epidemiology and health economics, in order to better be able to investigate the epidemiological burden as well as economic burden of brain disorders in Europe.
Collaboration between epidemiologists and economists
The present research project initiated a close collaboration between epidemiologic experts in the disease areas included under brain disorders, as well as health economic experts in the field. The need to combine the expertise of the two research fields became very clear and leverages the quality of the final results of such a study. The hope is that this close collaboration shall be fostered further in order to be able to fill the gaps of knowledge of brain disorders in Europe. This is particularly important for addressing two methodological problems identified in this study: The need to collect epidemiological and costs data in a way that address the issue of comorbidities, and the need to make the estimates of prevalence of the disease compatible with the cost per case estimates;
i.e. to make sure that the cost per case can be multiplied with the number of cases in a consistent way to arrive at a valid estimate of the total cost of the disease.
Implications for European research policy
Previous data showing that disorders of the brain account for 35% of the burden of all diseases in Europe (Olesen and Leonardi, 2003) are now supported by economic data from the present study. It showed that costs of disorders of the brain are enormous and considerably larger than costs of diabetes or cancer. In fact, the costs of brain disorders are bigger than the costs of diabetes and cancer combined, corresponding to the WHO data on the burden of diseases. The latter studies have shown that the burden of brain diseases (and therefore also of costs of brain disorders) will increase markedly during the next two decades due to the ageing population in Europe. The only way to counteract this explosion in cost, which is a major threat to the economic welfare in Europe, is by increased research efforts. Better prevention, better treatments and better health care systems are mandatory. The time to achieve this is short which calls for immediate action. In the fifth Framework Programme (FWP) of the European Union (1998) (1999) (2000) (2001) (2002) , €85 million was spent on neuroscience (Sautter et al., 2003) . This makes up 0.01% of our estimated cost of brain disorders in Europe or €17 million per year. A draft programme for such action has been suggested by the EBC and will be developed into a full consensus programme for future brain research in Europe within the next year. This programme calls for an increase in brain research to €500 million per year or 0.13% of the annual costs of brain disorders. Compared with the Lisbon goals to spend 2% of gross national product (GNP) on research and development, this is a tiny figure even considering that research expenses at the national level are much higher than at the European level. However, relatively speaking, it would represent a huge increase as in the sixth FWP only 8% of the life science research budget was spent on brain research.
European Union spending on brain research is thus not only of a very small absolute magnitude but the proportion spent on brain research is also incommensurable with the enormous costs of these disorders, not to speak of the immense importance of a better understanding of how the brain normally works.
Implications for European health care policy
As discussed above, the WHO data on burden and the present economic data have established beyond doubt that brain disorders represent the most burdensome and costly group of diseases to society. They consume, however, only 15% of direct health care costs in Europe. There is thus a discrepancy between the impact of these disorders and direct health care spending. Part of this may be due to smaller possibilities to treat or cure these disorders compared with other fields. Whilst this may have been true in the past, a host of new drugs and other treatments have revolutionized the treatment of brain disorders in recent decades. It seems worth investigating whether the distribution of direct health care costs reflect traditional beliefs rather than present day therapeutic possibilities. It is not unusual that new treatment possibilities in health care remain under resourced for many years. Furthermore, rather than increased resources, psychiatry has witnessed a dramatic reduction in beds and resources in most western European countries which could have caused increased morbidity and crime. Such trends must be analysed in prospective studies and may provide invaluable guidance for future health investments.
It is often stated that drugs for brain diseases are overused and too costly. However, drugs for brain disorders accounted for only 8% of total drug sales contrasting the high relative and absolute costs of brain disorders. Furthermore, they represent only 3% of the total cost of these disorders. If these drugs reduce other costs of brain disorders by 3% then they have earned back what they cost. Considering that they keep large numbers of patients out of hospital, in employment and lead to less short-term absenteeism from work, the likelihood is that they save many times their own cost. Again, prospective health economic studies are necessary to prove such statements and to provide exact figures.
On balance, it seems clear already from existing figures for health expenditure that further investment in brain health will be very profitable to society.
Implications for medical school and other health educational curricula
Medical school curriculum should of course reflect the importance of the various diseases that doctors are to encounter in their professional life. However, there should not necessarily be identity between the relative burden or relative cost of a group of diseases and the per cent of curriculum devoted to the problem. The therapeutic possibilities are also important and those diseases where extensive treatment possibilities exist should receive more attention than diseases where therapeutic possibilities are significantly smaller.
We have not extensively searched and analysed the curricula in medical schools in Europe. This remains to be carried out by future studies having that focus. However, there is no doubt that teaching in basic and clinical brain related subjects is grossly smaller than the Cost of disorders of the brain in Europe burden and cost of brain disorders also considering the therapeutic possibilities available today. In most medical schools, the curriculum still reflects the therapeutic nihilism that characterized brain disorders 50 years ago and not modern day therapeutic possibilities.
Hopefully, the data presented here will stimulate prospective analysis of the teaching of brain sciences at medical schools and in all other health science educations in the future, so that health care professionals of tomorrow will be able to cope better with the huge burden and cost of disorders of the brain.
Conclusions and recommendations
In EU countries, Norway, Iceland and Switzerland with a population of 466 million people, an estimated 127 million Europeans currently suffer from one or more brain disorder. Brain disorders figure amongst the leading causes of death and disability. Yet, the knowledge of the epidemiological and economic impact of brain disorders has been relatively little researched in Europe. The present study estimated the total cost of brain disorders in Europe to €386 billion in 2004 prices, which corresponds to a cost of €829 per European inhabitant. Direct medical expenditures alone totalled $135 billion, comprised of inpatient stays (€78 billion), outpatient visits (€45 billion) and drug cost (€13 billion). Attributable indirect costs resulting from lost workdays and productivity loss due to permanent disability and mortality amounted to €179 billion. Direct non-medical costs (social services, informal care and other direct costs) totalled €72 billion. Our estimate only includes the most prevalent brain disorders. Due to scarcity of data, our total cost results only partially include direct non-medical cost (e.g. community care and informal care) and indirect costs, and omits completely intangible costs. We have by example shown that the cost of dementia increase with 25% when including informal care and the cost of multiple sclerosis increases with at least 50% when including intangible costs. The cost of brain disorders varied considerably from country to country, mostly explained by national variation in income.
Brain disorders receive only 15% of direct healthcare spending and 8% of total drug sales, the latter constituting 3% of the cost of brain disorders.
The current project bases its estimates on published data, and such data were largely missing in the new admission countries and also for many diseases from the old EU countries. Furthermore, data sources were often difficult to compare and cost categories were often missing.
Our study probably underestimates the full economic burden of brain disorder in Europe. Our study has exclusively evaluated the published evidence. This has identified major shortcomings in the epidemiologic and economic knowledge of brain disorders in Europe. Furthermore, treatment patterns and care provided to patients change over time. In order to better understand the impact of brain disorders to European society prospective field studies are needed in all disorders of the brain. These efforts need to be done in close collaboration between epidemiologic experts and health economic experts in the field.
